Physician profile
Bridget A Bonello
NPI 1184942138
$13,120.30
in general payments reported to CMS, 2019-2025
26 companies · $3,347 in 2025
The $3,347 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,288 · 2022: $2,876 · 2023: $2,026 · 2024: $2,582 · 2025: $3,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,852 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,851.55 |
| Education | $103.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,378.41 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,881.29 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,385.24 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $941.45 | 2021-2025 | Entyvio, Eohilia |
| Pfizer INC. | $825.27 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $804.28 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $601.33 | 2021-2024 | Livdelzi, Epclusa |
| Ardelyx, INC. | $448.52 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $386.04 | 2021-2024 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $324.55 | 2021-2024 | |
| Lilly USA, LLC | $321.41 | 2022-2025 | Omvoh |
| Celgene Corporation | $302.70 | 2021-2024 | Zeposia |
| Genzyme Corporation | $302.41 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $171.59 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $147.99 | 2024 | Sucraid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $131.70 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $129.99 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $103.52 | 2024-2025 | Vowst |
| Ipsen Biopharmaceuticals, INC | $101.81 | 2024-2025 | Iqirvo, Bylvay |
| Novo Nordisk INC | $89.09 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $83.03 | 2021-2023 | |
| Vivus LLC | $72.47 | 2021-2022 | |
| Evoke Pharma, INC. | $67.18 | 2021-2023 | Gimoti |
| Redhill Biopharma INC. | $53.03 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Merck Sharp & Dohme LLC | $51.33 | 2021 | |
| Daiichi Sankyo INC. | $14.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Bonello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.